FDA Clears CT-Based AI Software for Enhanced Detection of Usual Interstitial Pneumonia
The IQ-UIP AI software may bolster computed tomography diagnosis of usual interstitial pneumonia (UIP), which is reportedly misdiagnosed in over 50 percent of cases.
The Food and Drug Administration (FDA) has granted 510(k) clearance for IQ-UIP, an artificial intelligence (AI)-powered software for enhancing computed tomography (CT) diagnosis of usual interstitial pneumonia (UIP).
Leveraging deep learning technology, IQ-UIP provides automated analysis of conventional CT scans with rapid detection of UIP patterns such as honeycombing and subpleural fibrosis, according to 4DMedical, the developer of IQ-UIP.
In addition to facilitating improved detection of usual interstitial pneumonia (UIP) on standard CT scans, 4DMedical says the newly FDA-cleared AI software IQ-UIP provides automated referral workflows for specialists who treat UIP. (Image courtesy of RadiologyinThai.com )
Emphasizing that more than 50 percent of UIP is initially misdiagnosed, 4DMedical noted the condition’s non-specific symptomatology may mimic other conditions such as asthma and chronic obstructive pulmonary disease (COPD).
In addition to a rapid diagnosis of UIP, which is characterized by chronic inflammation and progressive lung fibrosis, 4DMedical said IQ-UIP provides automated referral workflows for specialists, facilitating timely care for a condition that has a median survival of one to two years after diagnosis.
Recent Videos
Related Content
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025Article
In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for cases > CAD-RADS 4A.
